First human studies with a high-molecular-weight iron chelator

Journal of Laboratory and Clinical Medicine

Volumn 135, Issue 1, 2000, Pages 57-65

  Dragsten, Paul R ^a,b,c   Hallaway, Philip E ^a,b,c   Hanson, Gregory J ^a,b,c   Berger, Arthur E ^a,b,c   Bernard, Bruce ^a,b,c   Hedlund, Bo E ^a,b,c  

^a SRA International Inc ^*  (United States)

^b District of Columbia   (United States)

^c GENERAL DYNAMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033989136     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(00)70021-7     Document Type: Article

References (55)

1. 1. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J 1982;284:1081-4.
2. 2. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis and therapy. CRC Crit. Rev Clin Lab Sci 1983;19:205-65.
3. 3. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 1995;32:304-12.
4. 4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
5. 5. Giardini C. Treatment of β-thalassemia. Curr Opin Hematol 1997;4:79-87.
6. 6. Porter J. A Risk-benefit assessment of iron-chelation therapy. Drug Safety 1997;17:407-21.
7. 7. Lenfant C. Cooley’s anemia: progress in biology and medicine (NIH report, 1995).
8. 8. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
9. 9. Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984;311:140-4.
10. 10. Allain P, Chaleil D, Mauras Y, et al. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. Clin Chim Acta 1987;170:331-8.
11. 11. Chang TMS, Barre P. Effect of desferrioxamine on removal of aluminium and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983;2(8358):1051-3.
12. 12. Yokel RA, Ackrill P, Burgess E, et al. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. J Toxicol Environ Health 1996;48:667-83.
13. 13. Bia MJ, Cooper K, Schnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989;36:852-8.
14. 14. Hernandez P, Johnson CA. Deferoxamine for aluminum toxicity in dialysis patients. ANNA J 1990;17:224-8.
15. 15. Nicholas JC, Dawes PT, Davies SJ, Freemont AJ. Persisting aluminium-related bone disease after cadaveric renal transplantation. Nephrol Dial Transplant 1999;14:202-4.
16. 16. Yokel RA. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J Toxicol Environ Health 1994;41:131-74.
17. 17. Bauer M, Feucht K, Ziegenfuss T, Marzi I. Attenuation of shock-induced hepatic microcirculatory disturbances by the use of a starch-deferoxamine conjugate for resuscitation. Crit Care Med 1995;23:316-22.
18. 18. Bauer M, Ziegenfuss T, Feucht K, Marzi T. Acute resuscitation with pentastarch-conjugated deferoxamine vs. Conventional pentastarch: comparative effects on macro-and micro-circulation following hemorrhagic shock. In: Faist E, Baue AE, Schildberg FW, editors. The immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches (vol I and II). Scottsdale, AZ: Pabst Science Publishers; 1997. p. 972-9.
19. 19. Jacobs DM, Julsrud FM, Bubrick MP. Iron chelation with a deferoxamine conjugate in hemorrhagic shock. J Surg Res 1991;51:484-90.
20. 20. Rose S, Geiselmann A, Bauer M, Dike J, Marzi I. Prevention of oxidant injury by HES-deferoxamine-conjugate during hemorrhagic shock in the rat. In: Faist E, Baue AE, Thijs L, editors. Third International Congress on the Immune Consequences of Trauma, Shock and Sepsis. Munich, Germany: Intensive Care Medicine (Springer International); 1994. p. S129.
21. 21. LaLonde C, Knox J, Youn Y-K, Demling R. Burn edema is accentuated by a moderate smoke inhalation injury in sheep. Surgery 1992;112:908-17.
22. 22. Demling R, LaLonde C, Knox J, Youn Y-K, Zhu D, Daryani R. Fluid resuscitation with deferoxamine prevents systemic burn-induced oxidant injury. J Trauma 1991;31:538-44.
23. 23. Mousa SA, Ritger RC, Smith RD. Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch. Cardiovasc Pharmacol 1992;19:425-9.
24. 24. Maruyama M, Pieper GM, Kalyanaraman B, Hallaway PE, Hedlund BE, Gross GJ. Effects of hydroxyethyl starch conjugated deferoxamine on myocardial functional recovery following coronary occlusion and reperfusion in dogs. J Cardiovasc Pharmacol 1991;17:166-75.
25. 25. Drugas GT, Paidas CN, Yahanda AM, Ferguson D, Clemens MG. Conjugated desferoxamine attenuates hepatic microvascular injury following ischemia/reperfusion. Circ Shock 1991;34:278-83.
26. 26. Fantini GA, Yoshioka T. Deferoxamine prevents lipid peroxidation and attenuates reoxygenation injury in postischemic skeletal muscle. Am J Physiol 1993;264:H1953-9.
27. 27. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med 1989;7:645-51.
28. 28. Gehlbach P, Purple RL. Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. Invest Ophthalmol Vis Sci 1994;35:669-76.
29. 29. Palmer C, Roberts RL, Bero C. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 1994; 25:1039-45.
30. 30. Voest EE, Vreugdenhil G, Marx JJM. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994;120:490-9.
31. 31. Hallaway PE, Hedlund BE. Therapeutic strategies to inhibit iron-catalyzed tissue damage. In: Lauffer RB, editor. Iron and human disease. Boca Raton, FL: CRC Press; 1992. p. 477-508.
32. 32. Hedlund BE, Hallaway PE. Role of iron and oxygen radicals in hemorrhage and shock. Klin Wochenschr 1991;69: 1113-7.
33. 33. Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501-14.
34. 34. Sanan S, Sharma G, Malhotra R, Sanan DP, Jain P, Vadhera P. Protection by desferrioxamine against histopathological changes of the liver in the post-oligaemic phase of clinical hemorrhagic shock in dogs: correlation with improved survival rate and recovery. Free Radic Res Commun 1989;6:29-38.
35. 35. Kirschner RE, Fantini GA. Role of iron and oxygen-derived free radicals in ischemia-reperfusion injury. J Am Coll Surg 1994;179:103-17.
36. 36. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63.
37. 37. Bentur Y, McGuigan M, Koren G. Deferoxamine(desferrioxamine). New toxicities for an old drug. Drug Safety 1991;6:37-46.
38. 38. Hallaway PE, Eaton JW, Panter SS, Hedlund BE. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci 1989;86:10108-12.
39. 39. Lee P, Mohammed N, Marshall L, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 1993;21:640-4.
40. 40. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979;42:547-55.
41. 41. Allain P, Mauras Y, Chaleil D, et al. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol 1987;24:207-12.
42. 42. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs. In: Code of Federal Regulations, Title 21, Part 210: 1998.
43. 43. United States Pharmacopeial Convention I. The United States Pharmacopeia (vol 27). Taunton, MA: Rand McNally, 1995.
44. 44. Emery T. Exchange of iron by gallium in siderophores. Biochemistry 1986;25:4629-33.
45. 45. Artiss D, Vinogradov S, Zak B. Spectrophotometric study of several sensitive reagents for serum iron. Clin Biochem 1981;14:311-5.
46. 46. Whitten CF, Gibson GW, Good MH, Goodwin JF, Brough AJ. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations. Pediatrics 1965;36:322-35.
47. 47. Forder JR, McClanahan TB, Gallagher KP, Hedlund BE, Hallaway PE, Shlafer M. Hemodynamic effects of intraatrial administration of deferoxamine or deferoxaminepentafraction conjugate to conscious dogs. J Cardiovas Pharmacol 1990;16:742-9.
48. 48. Hallberg L, Hedenberg L. Desferrioxamine-induced urinary iron excretion in normal and iron-deficient subjects. Scand J Haematol 1967;4:11-20.
49. 49. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-30.
50. 50. Donfrancesco A, Deb G, Angioni A, et al. D-CECaT: a break-through for patients with neuroblastoma. Anti-Cancer Drugs 1993;4:317-21.
51. 51. Estrov Z, Tawa A, Wang X-M, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987;69:757-61.
52. 52. Polson RJ, Jawed A, Bomford A, Berry H, Williams R. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br Med J 1985;291:448.
53. 53. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. J Clin Invest 1995;96:1159-63.
54. 54. Pieper GM, Siebeneich W. Diabetes-induced endothelial dysfunction is prevented by chronic treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol 1997;30:734-8.
55. 55. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali J-R, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by 1-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998;97:736-43.